Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia

BMC Public Health

Sibhatu Biadgilign¹  Fasil Tessema¹  Amare Deribew¹  Mesele Mindachew² 

[1] Department of Epidemiology, College of Public Health and Medical Science, Jimma University, Jimma, Ethiopia;Department of General Public Health, College of Public Health and Medical Science, Jimma University, Jimma, Ethiopia

关键词: Ethiopia;    HIV;    Isoniazid Preventive Therapy;    TB;    Adherence;   

Others  :  1164020
DOI  :  10.1186/1471-2458-11-916

 received in 2011-04-12, accepted in 2011-12-12,  发布年份 2011

【 摘 要 】

Background

Isoniazide preventive therapy (IPT) is given to individuals with latent infection of tuberculosis (TB) to prevent the progression to active disease. One of the primary reasons for failure of IPT is poor adherence.

Methods

A cross sectional study was conducted in four hospitals in Addis Ababa. Data were collected using a pre-tested interviewer-administered structured questionnaire. Bivariate and multivariate analysis was done to identify predictors of IPT.

Results

A total of 319 (97.5%) individual participated in this study. Within seven days recall period, self-reported dose adherence rate was 86.5%. Individual who received explanation about IPT from health care providers (OR = 7.74; 95%CI: 3.144, 19.058); who had good feeling/comfortable to take IPT in front of other people [OR = 5.981, 95%CI (2.308, 15.502)] and who attended clinical appointment regularly (OR = 4.0; 95%CI: 1.062, 15.073) were more likely to adhere to IPT. Participants who developed IPT related adverse effect were 93% less likely to adhere to the prescribed doses (OR = 0.065; 95%CI: 0.024, 0.179).

Conclusion

The prevalence of self reported dose adherence over the past 7 days was higher. Non-adherence was observed among respondent who were not provided with sufficient information about IPT. The health care providers need to strengthen their educational and counseling efforts to convince the patient before putting them on IPT. To enhance adherence, health education efforts should focus on the importance of IPT, the details of the regimen and adverse effects.

【 授权许可】

   
2011 Mindachew et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Smoll M, Shafer F: An out breaks of tuberculosis with accelerated progression among person infected with HIV. New Engl J Med 2006, 326:213-35.
• [2]World Health Organization (WHO): Global Tuberculosis Control--surveillance, Planning, Financing. WHO/HTM/TB/2006.362. Geneva: WHO; 2006.
• [3]Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC: Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005, 293:2767-75.
• [4]MOH: AIDS in Ethiopia, disease prevention and control department of ministry of health. 4th edition. 2008.
• [5]Moulding T, Dutt A, Reichman L: Fixed-dose combinations of anti tuberculosis medications to prevent drug resistance. Ann Intern Med 2006, 122:951-54.
• [6]WHO/UNAIDS: Policy Statement on Preventive Therapy Against Tuberculosis in People Living with HIV.WHO/TB/98.255. Geneva: WHO; 2005.
• [7]MOH: Implementation Guidelines for TB/HIV Collaborative Activities in Ethiopia. Addis Ababa: Federal Ministry of Health; 2008.
• [8]International Union against Tuberculosis and Lung Disease, Global Program on AIDS, World Health Organization: Tuberculosis preventive therapy in HIV-infected individuals. A joint statement of the International Union Against Tuberculosis and Lung Disease (IUATLD) and the Global Program on AIDS and the Tuberculosis Program of the World Health Organization (WHO). Tubercle Lung Dis 1994, 75:96-98.
• [9]Besch CL: Compliance in clinical trials. AIDS 2004, 9(1):1-10.
• [10]Winkvist A, Diwan V: Adherence to IPT among HIV infected person in Chaiang Rai Thailand. AIDS 2007, 11:107-112.
• [11]Foster S, Godfry-Faussett P, Porter , Modeiling J: Adherence to tuberculosis preventive therapy for people live with HIV; the example of Uganda. AIDS 2002, 11(3):919-925.
• [12]Rowe K, Makhubele J, Hargreaves R: Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings? Int J Tuberc Lung Dis 2005, 9(3):263-269.
• [13]Hiransuthikul N, Nelson KE, Hiransuthikul P, Vorayingyong A, Paewplot R: INH preventive therapy among adult HIV-infected patients in Thailand. Int J Tuberc Lung Dis 2005, 9(3):270-5.
• [14]Szakacs TA, Wilson D, Cameron DW, Clark M, Kocheleff P, Muller FJ, McCarthy AE: Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. BMC Infect Dis 2006, 13:6:97.
• [15]Wilkinson D: Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomized placebo controlled trials. BMJ 2005, 317:625-629.
• [16]McCallum R: Effects of previous medication experience and health beliefs on intended compliance to an imagined regimen. J Compliance in Health Care 2007, 3:125-134.
• [17]Meichenbaum D, Turk D: Facilitating Treatment Adherence: A Practioner's Guidebook. New York: Plenum Press; 2006.
• [18]Rennie TW, Bothamley GH, Engova D, Bates IP: Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J 2007, 30:728-735.
• [19]Dunbar J: Predictors of patient adherence: patient characteristics. In The Handbook of Health Behavior Change. Edited by Shumaker S, Schroon E, Ockene J. New York: Springer; 2004:348-360.
• [20]Bartlett EE: The effects of physician communications skills on patient satisfaction; recall, and adherence. J Chronic Dis 2001, 37(9-10):755-64.
• [21]Sbarbaro JA: The patient-physician relationship: compliance revisited. Ann Allergy 2006, 64(4):325-31.
• [22]Clark NM: Impact of education for physicians on patient outcomes. Pediatrics 2004, 101(5):831-6.
• [23]Clark NM: Long-term effects of asthma education for physicians on patient satisfaction and use of health services. Eur Respir J 2000, 16(1):15-21.
• [24]Stewart MA: Effective physician-patient communication and health outcomes: a review. Can Med Assoc J 2006, 152(9):1423-33.
• [25]Mead N, Bower P: Patient-centered consultations and outcomes in primary care: a review of the literature. Patient Educ Couns 2002, 48(1):51-61.
• [26]Korsch BM, Negrete VF: Doctor-patient communication. Sci Am 2003, 227(2):66-74.
• [27]Xu W, Lu W, Zhou Y, Zhu L, Shen H, Wang J: Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study. BMC Health Serv Res 2009, 9:169. BioMed Central Full Text
• [28]Munseri PJ, Talbot EA, Mtei L, Fordham von Reyn C: Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis 2008, 12:1037-1041.
• [29]Philip A, LoBue , Kathleen S, Moser : Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003, 168:443-447.
• [30]Page KR, Sifakis F, Montes de Oca R, et al.: Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis. Arch Intern Med 2006, 166:1863-1870.
• [31]Kwara A, Herold JS, Machan JT, Carter EJ: Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest 2008, 133(4):862-8.
• [32]Horne R, Weinman J: Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychoomat Res 1999, 47:555-567.
• [33]Hirsch-Moverman Y, Bethel J, Colson PW, Franks J, El-Sadr W: Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis 2010, 14:1104-11.
• [34]Naing NN, D'Este C, Isa AR, Salleh R, Bakar N, Mahmod MR: Factors contributing to poor compliance with anti-TB treatment among tuberculosis patients. Southeast Asian J Trop Med Public Health 2001, 32(2):369-82.
• [35]Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh CR Jr: Predictors of failure to complete treatment for latent tuberculosis infection. J Infect 2007, 54:262-266.
• [36]Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen JJ: Predicting non- completion of treatment for latent tuberculosis infection: a prospective survey. Am J Respir Crit Care Med 2006, 174:717-721.
• [37]Rosenstock IM: Patient compliance with health regimens. JAMA 1975, 234:402-3.
• [38]Sloan JP, Sloan MC: An assessment of default and non - compliance in tuberculosis control in Pakistan. Trans R Soc Trop Med Hyg 1981, 75:717-8.
• [39]Stewart MA: What is the successful doctor-patient interview? A study of interactions and outcomes. Soc Sci Med 1984, 19:167-75.
• [40]Barnhoorn F, Adriaanse H: In search of factors responsible for noncompliance among tuberculosis patients in Wardha District, India. Soc Sci Med 1992, 34(3):291-306.
• [41]O'Hanrahan M, O'Malley K: Compliance with drug treatment. Br Med J 283:298-300.
• [42]Alcabes P: Compliance with isoniazid prophylaxis in jail. Am Rev Respir Dis 2006, 140(5):1194-7.
• [43]Menzies R, Rocher I, Vissandjee B: Factors associated with compliance in treatment of tuberculosis. Tuber Lung Dis 2002, 74(1):32-7.
• [44]Janz NK, Becker MH: The Health Belief Model: a decade later. Health Educ Q 2004, 11(1):1-47.
• [45]Becker M: The health belief model and personal behavior. Health Educ Monogr 2000, 1:324-508.